Blog
Is Howmet (HWM) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm
Commercial Metals (CMC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Commercial Metals (CMC) reported $2.13 billion in revenue for the quarter ended February 2026, representing a year-over-year increase of 21.5%. EPS of $1.16 for the same period compares to $0.26 a
Wall Street Bulls Look Optimistic About Coca-Cola (KO): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)
Chewy (CHWY) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
For the quarter ended January 2026, Chewy (CHWY) reported revenue of $3.26 billion, up 0.5% over the same period last year. EPS came in at $0.27, compared to $0.28 in the year-ago quarter.
The
Compass Minerals Redeems 2027 Notes to Transform Balance Sheet
Compass Minerals International, Inc. CMP has made an announcement to fully redeem the $150 million aggregate principal amount outstanding of its 6.750% Senior Notes due 2027 in an attempt to
ALT Pemvidutide Explained: What Makes It Different in MASH
Altimmune ALT is advancing pemvidutide as a differentiated approach to serious liver diseases where effective options remain limited.
The key question for investors is whether pemvidutide’s
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
An updated edition of the February 5, 2026, article.
The global oncology market is entering a period of rapid evolution, fueled by rising cancer incidence, aging populations and continued scientific
5 Relative Price Strength Picks for Choppy Market Phases
Markets are navigating a tense phase, with oil prices surging as the Middle East uncertainty deepens. Reports of troop deployments and stalled negotiations initially pulled stocks lower, as
McCormick (MKC) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
In its upcoming report, McCormick (MKC) is predicted by Wall Street analysts to post quarterly earnings of $0.61 per share, reflecting an increase of 1.7% compared to the same period last year
Curious about Dave & Buster's (PLAY) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Analysts on Wall Street project that Dave & Buster's (PLAY) will announce quarterly earnings of $0.38 per share in its forthcoming report, representing a decline of 44.9% year over year. Revenues
Stay Ahead of the Game With Nike (NKE) Q3 Earnings: Wall Street's Insights on Key Metrics
Wall Street analysts forecast that Nike (NKE) will report quarterly earnings of $0.29 per share in its upcoming release, pointing to a year-over-year decline of 46.3%. It is anticipated that
MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates
MeiraGTx Holdings PLC (MGTX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.6 per share. This compares to a loss of $0.5 per share a year
Jabil, Inc. (JBL) Hits Fresh High: Is There Still Room to Run?
Have you been paying attention to shares of Jabil (JBL)? Shares have been on the move with the stock up 2% over the past month. The stock hit a new 52-week high of $283.76 in the previous session
AAR Corp. (AIR) Hit a 52 Week High, Can the Run Continue?
Have you been paying attention to shares of AAR (AIR)? Shares have been on the move with the stock up 1.3% over the past month. The stock hit a new 52-week high of $122.97 in the previous session
FactSet (FDS) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
The upcoming report from FactSet Research (FDS) is expected to reveal quarterly earnings of $4.37 per share, indicating an increase of 2.1% compared to the year-ago period. Analysts forecast
Seeking Clues to TD SYNNEX (SNX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
In its upcoming report, TD SYNNEX (SNX) is predicted by Wall Street analysts to post quarterly earnings of $3.26 per share, reflecting an increase of 16.4% compared to the same period last year
Here's Why You Should Retain Accenture Stock in Your Portfolio Now
Accenture plc ACN has an encouraging earnings surprise history, having surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 3.88%
ACN’s
Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.19 per share a year ago. These
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
Here's an eye-opening statistic: older Americans are more afraid of running out of money than of death itself.
And older Americans have legitimate reasons for this worry, even if they have dutifully
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio
Integer Holdings Corporation ITGR has been gaining from its research and product development activities. The optimism, led by a solid fourth-quarter 2025 performance and its strength in product
3 Miscellaneous Food Stocks to Buy Amid Huge Short-Term Price Upside
The Zacks-defined Food-Miscellaneous industry is facing ongoing challenges from inflation, cautious consumer spending and soft foodservice demand, leading to volume pressure and increased
Will GM's $600M Korea Push Ease Exit Worries for Good?
U.S. legacy automaker General Motors GM is doubling down on its Korean operations with a $600 million investment. This move comes at a time when questions linger about its long-term presence in the
PacBio Wins Basecamp Research Deal for Trillion Gene Atlas Initiative
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, recently announced that Basecamp Research has selected its HiFi sequencing technology on the Revio system to support the
Is AUNA S.A. a Solid Investment Opportunity Post Q4 Earnings?
Auna S.A. AUNA released its fourth-quarter 2025 earnings report on March 10. The Latin America-based healthcare platform’s revenue and adjusted net income increased on a year-over-year basis. While
J&J's Pipeline Surge Sets Up Stronger Growth From New Drugs in 2026
Johnson & Johnson JNJ has a strong R&D pipeline, with primary focus areas being immunology, oncology and neuroscience.
J&J rapidly advanced its pipeline in 2025, attaining significant clinical and


